Podcasts about patients

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

As patients, we often wonder what our role should be when it comes to getting better. Should we research options, get second opinions, and ask lots of questions? Or should we sit back, and let the health care professionals take charge? When does it make sense to push, and when is it best to do less?On this episode, we examine our role as patients, the choices we make, and charting our path toward better health. A reporter gets a wake-up call while looking into diabetes rates among Latinos in Oklahoma, we hear about one woman's choice to forgo cancer treatment — and how her family and doctors responded, and we explore a controversial proposed diagnosis for severe, long-term anorexia. SHOW NOTES: First Juliet Wayne's brother died from cancer — then her long-term partner broke up with her. That was followed by a deep depression; and then, the nightmares started. We talk with Wayne about how these nightmares affected her life, why doctors said she couldn't take a drug designed to stop them, and how a chance encounter finally led her to relief. Historian Joy Lisi Rankin talks about her mother's choice not to pursue treatment for breast cancer — and how Rankin's own experience years later with breast cancer treatment changed how she felt about her mother's choices. You can read Rankin's essay about her mother at Stat News. Anorexia has one of, if not the, highest mortality rates of any mental illness, with a relatively low recovery rate. Patients and their families suffer deeply from this illness, which can last for decades. In 2022, a paper proposed a new and controversial diagnosis: terminal anorexia. Reporter Elizabeth Zwerling tells the story of how this diagnosis came to be proposed, and the difficult conversations it kicked off in the world of eating disorder treatment.

On this episode of the Orange and Brown Talk podcast, Mary Kay Cabot, Ashley Bastock and Dan Labbe get into the future of the Browns quarterback position, centered around Shedeur Sanders. They start by dissecting Sanders' weekly press conference, covering his mindset of laying a foundation, the advice he received from Jameis Winston and his ongoing efforts to build chemistry with his receivers. The discussion then explores the central 'dichotomy' facing the team: Can they afford to be patient with a developing rookie when the Super Bowl window for veterans like Myles Garrett is closing? With a potential top draft pick looming, the pressure is on. They also delve into the significant uncertainty surrounding the coaching staff and front office. They debate whether Kevin Stefanski and Andrew Berry will return and how those decisions will ultimately shape the most important position on the team. Who will be making the call on the Browns' quarterback in 2026, and what will that decision be? Follow us: On X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/orangebrowntalk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ YouTube: h⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ttps://www.youtube.com/@ClevelandBrownsonclevelandcom⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/orangeandbrowntalk/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Music credits: Ice Flow by Kevin MacLeod Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://incompetech.filmmusic.io/song/3898-ice-flow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ License: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://filmmusic.io/standard-license⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Gladden Longevity podcast, Dr. Jeffrey Gladden interviews Dr. Bernard Straile, a chiropractic physician who has transitioned from traditional chiropractic methods to energy medicine. They discuss the connection between inflammation and various health issues, the importance of bio-energetic evaluations, and the role of genetic testing in understanding health. Dr. Straile explains his innovative IMATE system, which uses frequencies to address genetic expression and inflammation. The conversation also covers the significance of epigenetics, the therapeutic applications of frequency treatments, and the holistic approach to healing chronic conditions. Dr. Straile shares insights on treatment success rates and the commitment required for effective healing, emphasizing the need for a comprehensive understanding of health beyond conventional methods.   For Audience ·       Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways   ·        Dr. Straile emphasizes the importance of understanding inflammation as a root cause of many health issues. ·        The IMATE system allows for bio-energetic evaluations to assess genetic expression. ·        Frequencies play a crucial role in addressing health conditions and genetic mutations. ·        Epigenetics can help overcome genetic mutations and influence health outcomes. ·        Therapeutic applications of frequency treatments can lead to significant health improvements. ·        A holistic approach is necessary to address the multiple causes of inflammation and pain. ·        Dr. Straile has a high success rate in treating chronic conditions, often above 90%. ·        Patients must commit to a series of treatments for effective healing. ·        The connection between genes and environmental factors is vital for health management. ·        Dr. Straile's book, '1000 Shades of Pink,' details case studies and treatment protocols.     Chapters 00:00 Introduction to Longevity and Energy Medicine 04:37 Understanding Inflammation and Its Root Causes 07:10 Bio-Energetic Evaluation and Genetic Insights 11:39 The Role of Frequencies in Health 13:59 Epigenetics and Gene Expression 16:13 Therapeutic Applications of IMAET Technology 21:35 Results and Impacts of Bio-Energetic Treatments 24:16 Exploring Scalar Waves and Their Significance 25:41 Understanding Inflammation and Back Pain 28:48 The Show Method: A Holistic Approach to Healing 29:55 Frequency Treatments: Addressing Inflammation 34:25 Navigating Complex Inflammation Causes 38:27 Integrating Technology in Healing 42:10 Exploring Energy Medicine and Future Directions To learn more about Dr. Bernard: Email: smarthealth4you@gmail.com Website: https://www.smarthealth4u.org/, www.imaet.com   Got a question for Dr. Gladden? Submit it using the link below and it might be answered in our next Q&A episode! https://form.typeform.com/to/tIyzUai7?   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw    

In today's episode of the PT on ICE Podcast, ICE CEO Jeff Moore & Dry Needling division lead faculty Ellison Melrose shares her extensive experience as a primary faculty member in the dry needling division, discussing both the upper and lower quarter techniques. She emphasizes the transformative potential of the new course for pelvic health practitioners and highlights her background in pelvic health education. Throughout the conversation, Elli candidly addresses the effectiveness of dry needling, noting instances where it significantly enhances patient outcomes. Tune in for valuable insights, tips, and a touch of humor as Elli recounts relatable parenting moments. Watch the episode or check out the full show notes on our blog at www.ptonice.com/blog If you're looking to learn more about our live dry needling courses, check out our dry needling certification which consists of Upper Body Dry Needling, Lower Body Dry Needling, and Advanced Dry Needling.

Send us a textThree year data from the LAMP Study - Atropine and your patients.---If you're considering or have ever considered getting a virtual team member for your practice check out hiredteem.com, mention The Myopia Podcast when signing up for a $250 dollar discount off of your first month's teem member.https://hireteem.com/myopia-podcast/

Send us a textWelcome back Rounds Table Listeners! In our year-end episode, Drs. Mike and John Fralick discuss five important research studies published in 2025:Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO) (0:00 – 4:20)Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) (4:21 – 9:30)Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC) (9:31 – 15:03)Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial (FRESH-UP) (15:04 – 18:09)Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) (18:10 – 23:49)The Good Stuff (23:50 – 25:27):Toronto Star Santa Claus Fund, Calgary Food Bank, The War Amps Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

In this episode Rachel is joined by her friend Aliza! Aliza's profession is in the mental health field, but her dating life seems to be as well. Aliza tells Rachel her crazy stories and what is wrong with these guys? Why do most of them seem like better candidates to be Aliza's patients than to be her husband? Aliza and Rachel also discuss how guys suddenly become different people as soon as they get your number. Aliza also tells Rachel about some of her work as a sex therapist and why it is such an important job in the Orthodox world. This is definitely an episode you don't want to miss!Shticky Situations is sponsored by CoronaCrush. To find out more information about CoronaCrush visit their website and coronacrush.co. Also join the CoronaCrush Facebook group and sign up for speed dating events!Remember to like the Shticky Situations page on Facebook, follow @shtickysituationspod on Instagram, and follow @shtickysituationspod on Tiktok! And make sure to join the Shticky Situations Loop Group:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://loopmein.app.link/invite?uuid=7bd5252c-c1ff-47fc-938b-1c319c57354e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Want to be a guest and hang out with Rachel and discuss your own dating stories? Apply today https://forms.gle/FhwZs74JBTJgGpw8A! Want to try your luck at dating Rachel or any of her guests? Also apply today https://forms.gle/J31HUQ5aYTzjz5Bv6! You can also send an email too shtickysituationspod@gmail.com or DM @shtickysituationspod on Instagram. Serious inquiries only.Shticky Situations is sponsored by Primrose Flower Shoppe! Primrose is located at 2922 Avenue M, Brooklyn, phone number 929-376-9815, and follow them on Instagram @primroseny.

Matt Vallière, Executive Director of the Patients' Rights Action Fund, joins John Catsimatidis & James Flippin as they substitute for Sid Rosenberg, to discuss the controversial assisted suicide bill. Valliere outlines the potential dangers of the bill, including the risks to vulnerable individuals who may be pressured or improperly qualified for lethal drugs. He highlights instances from other states and countries where similar legislation has led to troubling outcomes. The conversation explores the ethical, moral, and economic implications, particularly for people with disabilities, the elderly, and those in poverty. Valliere emphasizes that such laws propel a discriminatory mindset and erode the sanctity of life, calling it a complex issue cutting across faith, disability rights, and civil justice. Learn more about your ad choices. Visit megaphone.fm/adchoices

HOUR 3: More states signing on to "assisted suicide" for terminally ill patients. full 2093 Wed, 17 Dec 2025 22:00:00 +0000 dR744W0fFg1C5bq5Np3yk9GnTWEoAAYj news The Dana & Parks Podcast news HOUR 3: More states signing on to "assisted suicide" for terminally ill patients. You wanted it... Now here it is! Listen to each hour of the Dana & Parks Show whenever and wherever you want! © 2025 Audacy, Inc. News False https://pla

Mechanical ventilation doesn't have to feel like wizardry. In this podcast episode, we strip it back to what really matters—simple mental models, clean decision-making, and an approach that works whether you're in the back of a helicopter, a tight ambulance box, or a chaotic ED bay. We walk through the foundational concepts and the "why" behind each knob you touch. Then we zoom in on the Hamilton T1, the vent many of us love, hate, and still rely on every single shift. We cover what the T1 gets right, where people get tripped up, and how to let the machine work with you instead of against you. If you've ever wished mechanical ventilation felt less like memorizing settings and more like understanding physiology in motion, this episode will tighten up your practice and give you tools you can use on your very next flight or transport. Get CE hours for our podcast episodes HERE! -------------------------------------------- X @heavyhelmet Facebook @heavyliesthehelmet Instagram @heavyliesthehelmet Website heavyliesthehelmet.com Email contact@heavyliesthehelmet.com Disclaimer: Heavy Lies the Helmet's content is for educational purposes only and does not constitute medical advice. Always follow local guidelines and consult qualified professionals before applying any information. The hosts and guests are not responsible for errors, omissions, or outcomes. Views expressed are their own and do not reflect their employers or affiliates. --------------------------------------------  Crystals VIP by From The Dust | https://soundcloud.com/ftdmusic Music promoted by https://www.free-stock-music.com

If you find a doctor you trust, follow Dr. Kowey's advice: "hang on because they're not common people".In this candid conversation, Brigitte Cutshall welcomes Dr. Peter Kowey, cardiologist and author of "Failure to Treat", to discuss the deteriorating state of American healthcare. He has four decades of experience, reveals why the U.S. healthcare system is failing patients and doctors alike—and how we can reclaim the path to true healing.Dr. Kowey explores critical issues, including the shortage of primary care doctors, the burden on emergency rooms, the erosion of doctor-patient trust, and how financial pressures can compromise medical decision-making.Three Key Takeaways:(1) The primary care crisis is destroying healthcare foundations.(2) Trust and time are essential for healing.(3) Patients must become informed advocate.Visit https://peterkoweyauthor.com to learn more about Dr. Kowey's work and his book "Failure to Treat." For more authentic conversations on wellness, subscribe to Real Things Living.

Have you ever found yourself helping a loved one through a confusing medical situation and thought, "I wish I could do this full-time"? You're not alone. Many physicians are naturally drawn to patient advocacy and navigation, even if they don't yet realize it has a name or a career path. In this episode, I'm joined by Dr. Angie Ingraham, a former trauma surgeon and critical care physician who made a powerful career transition after her father's diagnosis with glioblastoma. Experiencing the healthcare system from the other side opened her eyes to the gaps patients and families face. That journey led her to launch True North Patient Advocates, where she now supports others through complex medical situations with clarity and compassion. Whether you've thought about becoming a patient advocate and navigator — or are simply curious about what this work actually involves — Angie shares the real-life steps she took to create a fulfilling and sustainable new path.   In this episode we're talking about: How a personal family crisis led Dr. Ingraham to explore patient navigation The surprising barriers patients face, even with medical connections What professional patient advocates and navigators actually do and how physicians are uniquely qualified How she built her business without formal business training The variety of clients and services in her day-to-day work Financial considerations and typical rates for advocates Steps you can take to explore this path for yourself You can find the show notes for this episode and more information by clicking here: www.doctorscrossing.com/episode236 Links for this episode: Dr. Angie Ingram — True North Patient Advocates Greater National Advocates Directory Alliance of Professional Health Advocates - Offers a Boot Camp and 100-day program for business startup Health Advocate X Patient Advocate Certification Board National Association of Healthcare Advocacy Work Episode #68: Being a Patient Advocate is a Real Option Episode #156: How To Start A Side Gig Or Business As A Patient Navigator  

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com What happens when AI meets real-world healthcare challenges? In this episode, Kali Ihde, Director of Northwestern Medicine's Ventures and Innovation, discusses how AI is being practically applied to enhance patient care and operational efficiency. She explains the importance of moving past hype, piloting AI solutions safely, and integrating them into workflows with input from clinicians and administrators. Kali highlights the growing AI literacy among healthcare professionals and shares how agentic AI is helping healthcare providers reach patients for preventive care while identifying risks such as elder abuse or suicidal ideation. She also emphasizes the need for structured evaluation and clear metrics to ensure that results are meaningful. Tune in to hear how Northwestern Medicine is leveraging AI to make a real difference in hospitals, clinics, and communities! Resources Connect with and follow Kali Ihde on LinkedIn. Follow Northwestern Medicine on LinkedIn and discover their website!

This week, we look at ctDNA-guided immunotherapy for bladder cancer, cardiovascular outcomes with tirzepatide, and evidence that one HPV vaccine dose may be enough. We explore high-dose rifampin for tuberculous meningitis, review measles amid rising outbreaks, and follow a challenging case of gastrointestinal bleeding. Essays examine how clinicians navigate post-Dobbs care, tobacco harm among people with mental illness, congenital syphilis, and sustaining medical research.

This episode is part of the special series Empowered Intimacy: Getting Your Sexy Back After Breast Cancer, where getting your sexy back is about reclaiming confidence, connection, and desire after a breast cancer diagnosis. Melissa Berry sits down with Chelsey Pickthorn, a patient advocate living with stage four triple-negative breast cancer, and Dr. Don Dizon, Chief of Hematology and Oncology at Tufts Medicine and a national leader in sexual health and inclusive cancer care.  They explore the challenges LGBTQ+ individuals face with intimacy, dating, body image, and relationships after a cancer diagnosis. Chelsey shares her experiences navigating disclosure, reconstruction, caregiving, and connection, while Dr. Dizon highlights gaps in healthcare for LGBTQ+ patients.  This honest and hopeful conversation offers guidance, empowerment, and advocacy for inclusive care. Thank you to Lilly, Merck, and Novartis for making this episode possible.  

The All Local Afternoon Update for Wednesday December 17th 2025

Guest: Jaclyn Tomsic MD DMD FACS https://www.instagram.com/doctorjacci/   Host: Serv Wahan MD DMD https://www.drwahan.com/   Keywords extractions, dental surgery, complications, tooth mobility, dental techniques, patient comfort, dry sockets, anticoagulation, dental tools, oral surgery, Serv Wahan, Jaclyn Tomsic, Dental Influencer, Dental Podcast Summary In this conversation, Dr. Serv Wahan and Dr. Tomsic discuss the intricacies of dental extractions, focusing on techniques, tools, and complications. They explore various approaches to tooth removal, the importance of patient comfort, and the management of complications such as dry sockets and infections. The discussion also touches on the protocols for patients on anticoagulation therapy and the significance of proper communication in dental referrals. Takeaways There's no one way to take teeth out; different techniques work for different practitioners. Mobility of the tooth is crucial before extraction; it helps in the process. Using bite blocks is essential for patient comfort during extractions. Anticoagulation therapy should not be stopped for single tooth extractions. Dry sockets can be managed with specific pastes and follow-up care. Communication with patients about their dental history is vital for successful extractions. Understanding the anatomy of the tooth and surrounding structures is key to successful extractions. Using the right tools and techniques can minimize complications during extractions. Patient education on post-operative care can prevent complications like dry sockets. Experience and adaptability in techniques improve extraction outcomes.  Titles Mastering Dental Extractions: Techniques and Tips Navigating Complications in Tooth Removal Sound bites "You have to have all the sizes." "It's not a race." "I don't like fracturing teeth." Chapters 00:00 Introduction to Extractions and Complications 03:01 Approaching Extractions: Techniques and Tools 06:03 Understanding Tooth Mobility and Elevation 09:02 Sectioning Techniques for Difficult Extractions 11:54 Managing Adjacent Teeth and Crowns 15:04 The Importance of Assistant Support 17:47 Advanced Techniques for Challenging Canines 20:54 Final Resort Techniques for Root Extraction 23:59 Extraction of Anterior Teeth 30:00 Exploring Extraction Techniques and Tools 41:58 Understanding Complications in Dental Extractions 54:01 Managing Post-Extraction Care and Patient Concerns

In part one of this two part series, Regan Robertson puts Dr. Chad Johnson and Dr. Maggie Augustyn in the interview seat to explore how contrast becomes a teacher in dentistry. Through real patient encounters, one centered on pricing pressure and another on a deeply personal boundary being crossed, the conversation examines how dentists are shaped by moments that do not feel productive at the time, but leave a lasting imprint on how they communicate, lead, and show up for patients. These are not ideal scenarios. They are real ones.  

Reports suggest around one-third of U.S. adults use continuous monitoring technology and health wearables…with trends showing persistent growth, especially among younger, educated, and higher-income individuals. And by providing 24/7/365, real-time data on physiological metrics like vital signs, glucose levels, and sleep patterns…continuous monitoring technology and health wearables are becoming increasingly powerful drivers of consumer behavior. And I believe this is super important, especially if you consider how more individuals began viewing themselves as consumers in the healthcare market compared to solely being patients. Also, with the help of continuous monitoring technology and health wearables…consumer healthcare has been evolving from a reactive, one-size-fits-all treatment approach to a distinctively proactive, personalized, and integrative data-led approach. Moreover, empowered by this "proactive health" mindset, consumers increasingly moving closer towards this four-way intersection of taste, convenience, nutrition, and functionality. Therefore, the most direct impact of continuous monitoring technology and health wearables is arguably the mainstreaming of the "food as medicine" philosophy. When consumers receive moment-by-moment feedback on how specific foods, beverages, and dietary supplements affect their bodies…they start demanding products tailored to their unique biological needs. But maybe the most significant example would be glycemic responses detected by continuous glucose monitors. In fact, whether boosted further by the recent FDA clearance for over-the-counter continuous glucose monitors and/or the rising usage of GLP-1 drugs for weight management…heightened interest in blood sugar management has also expanded beyond the diabetic community. Obviously, “war” had been waged on sugar a long time ago…but a “MAHA-influenced marketplace” has slightly shifted, with consumers being more comfortable with sweetness that has natural connotations. Either way, this signals a potentially powerful opportunity for packaged food and beverage companies to embrace diabetic-friendly products (for general wellness), as it's reasonable to imagine a similar adoption trajectory of gluten-free beyond those with celiac disease. Nonetheless, nearly 43% of consumers (today) associate healthy food with boosting performance, which means real-time data has increased demand for ingredients with measurable impacts, such as adaptogens for stress relief and nootropics for cognitive performance. Also, this influx of high-frequency biometric data can help shorten the product development cycle by providing functional CPG companies with "real-world evidence" that was previously unattainable. Next, these health technology wearables have opened a new engagement approach like how seeking to better reach the increasingly influential variations of the “wellness maxxing” internet community, marketers of functional CPG brands have begun showcasing wearable data in social storytelling to help prove product efficacy. While I totally understand the primary business cases involve premium positioning strategies…I'd bet that begins to change, as industry forward-thinkers recognize synthesizing this data into actionable low-cost, high-impact functional product solutions for broader populations is the REAL prize. Lastly, while continuous glucose monitoring revolutionized diabetes care…the same approach applied to inflammatory proteins could transform care for autoimmune diseases or other chronic diseases (i.e. cardiovascular health).

Starting your own medical practice can feel like stepping into an entirely different profession—and that's because in many ways, it is. Dr. Gina Maccarone, cosmetic surgeon and owner of The Surgeonista in Cincinnati, knows this tension well. After years in general surgery and trauma care, she made the leap to cosmetic surgery and private practice ownership.  Read the full show notes, memorable quotes, and key takeaways.  In this episode, Dr. Gina shares how authentic branding became her competitive advantage. From her signature pink color palette to her clear boundaries around patient selection, she's built a practice that attracts the right patients by simply being herself. We discuss why saying "no" to patients is actually a green flag, how AI and contractors can keep overhead manageable, and why clinical confidence doesn't automatically translate to business confidence.  Key topics covered:  Building authentic brand identity in healthcare  Managing patient expectations in cosmetic surgery  Using technology strategically to reduce costs  The challenge of delegating as a physician-owner  Learning from what you don't want to replicate    Find Dr. Maccarone:  Website  Instagram  Facebook  See Where Your Practice Stands: Take our Practice Growth Readiness Assessment  Connect With Us:  Be a Guest on the Show  Thriving Practice Community  Schedule Strategy Session with Tracy  Tracy's LinkedIn  Business LinkedIn Page  

2025 was the year AI agents moved from buzzword to real operational partners across the revenue cycle. In this episode, we look back at how eligibility, prior auth, document capture, and AR optimization all shifted toward faster, more predictable, and more proactive workflows.

Send us a textWhat does great IBD care look like when the system won't make it easy? We sit down with Dr. Adam Ehrlich, Section Chief of Gastroenterology at Temple Health and GI fellowship program director, to explore how he builds patient-centered care in an underserved setting—where insurance denials, missing records, and real-life logistics collide with complex disease.We talk about health literacy, trust, and the conversations that actually change outcomes. Adam explains how he frames risks and benefits with clarity, why the “risks of doing nothing” deserve equal airtime, and how he balances mode of therapy—IV, subcutaneous, or oral—against lifestyle, trauma history, pregnancy plans, and coverage rules. We dig into prison medicine's constraints, from medication access to policy barriers around scheduling, and the creative problem-solving required to keep patients safe and informed. He shares why being honest about uncertainty builds credibility, and how an early investment in patient education pays off with better monitoring and shared targets for remission.The episode also gets practical about personalization. We discuss drug levels with infliximab when severe colitis “loses” medication into the stool, when it's wise to de-escalate dosing, and how habits from flare days can persist after inflammation settles. Adam offers tools to retrain routines, navigate IBS overlap, and align care with quality of life goals like driving, work travel, and showing up at a kid's soccer game without anxiety. As a fellowship director, he reveals how he equips new gastroenterologists to handle today's broader therapy menu, think beyond flowcharts, and advocate through insurance barriers with persistence and purpose.If this conversation resonates, tap follow, share it with someone who needs it, and leave a quick review. Your support helps more people find practical, human-centered IBD care.Links and organizations to follow! Color of Gastrointestinal Illness (COGI)- mission to improve quality of life for BIPOC who are affected by IBD and other GI issues. The Stephanie A. Wynn Foundation - mission to eliminate health disparities and improve outcomes for individuals and communities affected by Inflammatory Bowel Diseases through comprehensive support services, with priority given to underserved populations facing the greatest barriers to healthcare.Strategic Alliance for Intercultural Advocacy in GI (SAIA)- mission to create culturally sensitive resources, research, and education for patients, caregivers and healthcare providers managing chronic GI conditions in order to minimize delays, dispel stigma, promote early diagnosis, and improve access to treatment for all.Let's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Starmer calls The Doctor strikes “Utterly irresponsible” Plus: Former Labour elected Mayor Jamie Driscoll joins the Greens, yet ANOTHER bad day for Keir Starmer, and GMP vow to clamp down even more on Pro-Palestine protesters. With: Michael Walker, Ash Sarkar, Dr Thomas Cheliotis-James & Jamie Driscoll

HOW MUCH DO DENTAL IMPLANTS COST!? Download the FREE Guide to Dental Implants Here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/3XPG2LSWant to know if you may be eligible for Permanent Teeth in 24 Hours? Take the 60-Sec Quiz Here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/4pBAQYa▬▬▬▬▬▬▬▬ Contents of this video ▬▬▬▬▬▬▬▬▬▬Disclaimer: Nuvia Dental Implant Centers are locally owned and operated by licensed dental practitioners. These locally owned and operated practices are part of a professional network of dental implant centers operated by prosthodontists, oral surgeons, and restorative dentists. Each Nuvia Dental Implant Center has a business affiliation with Nuvia MSO, LLC, a Dental Support Organization that provides non-clinical support to each center.*Nuvia Dental Implant Centers are able to provide patients with a bridge made with an FDA approved permanent material, zirconia, in 24-hours. No temporary denture. Not all those who come in for a consultation are medically cleared to receive permanent zirconia teeth in 24-hours. Follow up appointments are required to confirm implant integration and make adjustments if necessary. Results may vary in individual cases. Patients represented in videos are actual NUVIA patient(s) and may have been compensated for their time in telling their story.*While soft foods immediately after surgery are generally approved by our clinical team, the local surgeon may give individual instruction on dental implant aftercare according to the specific circumstances applicable to each case.To hear patient's speech after prosthetic placement please search Nuvia Dental Implant Center on YouTube and watch patient stories. *Individual results may vary based on a number of factors.Copyright 2024. Nuvia Dental Implant Centers. All rights reserved.

JHLT: The Podcast returns with an episode discussing the paper, "High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study," from the December issue of JHLT.   They are joined by the first author, Camille Miard, MD, and senior author, François Stéphan, MD, PhD, both from the cardiothoracic intensive care unit at Hôpital Marie Lannelongue in Paris.   The discussion explores: Whether antiphospholipid antibody titers could predict postoperative outcomes for CTEPH patients undergoing pulmonary endarterectomy (PEA) How APS patients differed from non-APS patients in the PEA cohort The changes in clinical practice at Marie Lannelongue after the study's findings   For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Please visit answersincme.com/NHE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.

Too busy to read the Lens? Listen to our weekly summary here! In this week's episode we discuss…Black, Asian, and Hispanic patients were more likely to have delays in initiation of treatment of nAMD.Patients taking GLP-1 receptor agonists had a 51.7% reduced risk of developing non-infectious uveitis.Implanting multifocal intraocular lenses in children showed improved visual acuity and stereopsis compared to a standard intraocular lens.

Bob Farrell, CEO of mPulse, is using digital technology, data analytics and AI to improve the relationship between health plans and their members in order to improve health outcomes and operational efficiency. Bob introduces the concept of HXI, Health Experience and Insights, as a framework that unites data, intelligence, and personalized communication to provide tools to enage members at the best time and by the preferred methods with appropriate information at the right time. Analyzing claims data enables plans to identify high-risk patients, promote preventive care, and build health literacy. Bob explains, "The mission of mPulse, and this has really been the mission of the company since its founding in 2015, is to improve the health outcomes of our customers' members and patients. So we're looking to close gaps in care. We're looking to increase literacy so that members and patients can understand their health plans. So providers can take charge of healthcare and improve those outcomes. And while we're doing that, we try to help our customers improve their operational efficiencies. Most of our customers are health plans and they range from small community plans to large nationals. The 60 largest plans are our customers. We have a wide array of customers and continue to expand on that base, both with new customers and by doing more with the customers that we have."   "Health plans are not known to be the early adopters of technology. So you're right. A lot of them are still transitioning from older ways of doing things. But in general, health plans have a huge trust issue with their members, and it has really resulted from a lack of engagement, a lack of positive experience. So we see a lot of health plans looking to embrace technology to improve the member experience, make sure that those members are getting outreach. Not just now and then, but during the whole course of their consumer health journey, so that they can be aware of what things they have available to them, so that they can easily adjudicate claims and easily find providers."    #mPulse #HXI #PersonalizedCare #HealthExperienceInsights #DigitalHealth mPulse.com Download the transcript here  

Bob Farrell, CEO of mPulse, is using digital technology, data analytics and AI to improve the relationship between health plans and their members in order to improve health outcomes and operational efficiency. Bob introduces the concept of HXI, Health Experience and Insights, as a framework that unites data, intelligence, and personalized communication to provide tools to enage members at the best time and by the preferred methods with appropriate information at the right time. Analyzing claims data enables plans to identify high-risk patients, promote preventive care, and build health literacy. Bob explains, "The mission of mPulse, and this has really been the mission of the company since its founding in 2015, is to improve the health outcomes of our customers' members and patients. So we're looking to close gaps in care. We're looking to increase literacy so that members and patients can understand their health plans. So providers can take charge of healthcare and improve those outcomes. And while we're doing that, we try to help our customers improve their operational efficiencies. Most of our customers are health plans and they range from small community plans to large nationals. The 60 largest plans are our customers. We have a wide array of customers and continue to expand on that base, both with new customers and by doing more with the customers that we have."   "Health plans are not known to be the early adopters of technology. So you're right. A lot of them are still transitioning from older ways of doing things. But in general, health plans have a huge trust issue with their members, and it has really resulted from a lack of engagement, a lack of positive experience. So we see a lot of health plans looking to embrace technology to improve the member experience, make sure that those members are getting outreach. Not just now and then, but during the whole course of their consumer health journey, so that they can be aware of what things they have available to them, so that they can easily adjudicate claims and easily find providers."    #mPulse #HXI #PersonalizedCare #HealthExperienceInsights #DigitalHealth mPulse.com Listen to the podcast here  

Chegou o episódio escolhido por vocês! Marcela Belleza e Joanne Alves convidam Carol Millon para conversar sobe 6 clinicagens de inibidores de SGLT2, as gliflozinas:Indicações além do DMRisco de CAD euglicêmicaQuando não usar?⁠Cuidados com doença aguda (sick day) e hipovolemia⁠Cuidados pré-operatórioRisco de fratura e amputaçãoReferências:1. Bailey CJ, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. Published 2013 Feb 20. doi:10.1186/1741-7015-11-432. Bersoff-Matcha SJ, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019;170(11):764-769. doi:10.7326/M19-00853. Chang HY, et al. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med. 2018;178(9):1190-1198. doi:10.1001/jamainternmed.2018.3034 4. Clar C, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012 Oct 18;2(5):e001007. doi: 10.1136/bmjopen-2012-001007. PMID: 23087012; PMCID: PMC3488745.5. Das SR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5. PMID: 32771263; PMCID: PMC7545583. 6. Fralick M, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. Published 2020 Aug 25. doi:10.1136/bmj.m28127. Li D, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348-355. doi:10.1111/dom.128258. Neal B, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223.e11. doi:10.1016/j.ahj.2013.05.0079. Nyirjesy P, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173-1178. doi:10.1185/03007995.2012.69705310. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/NEJMoa181174411. Rosenwasser RF, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. PMID: 24348059; PMCID: PMC3848644.12. Sridharan K, Sivaramakrishnan G. Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression. Expert Opin Drug Saf. 2025;24(7):797-804. doi:10.1080/14740338.2024.237775513. Ueda P,  et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. Published 2018 Nov 14. doi:10.1136/bmj.k436514. Watts NB, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18. PMID: 26580237; PMCID: PMC4701850.15. Zhuo M, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021;4(10):e2130762. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.3076216. Emerson Cestari Marino, Leandra Anália Freitas Negretto, Rogério Silicani Ribeiro, Denise Momesso, Alina Coutinho Rodrigues Feitosa, Marcos Tadashi Kakitani Toyoshima, Joaquim Custódio da Silva Junior, Sérgio Vencio, Marcio Weissheimer Lauria, João Roberto de Sá, Domingos A. Malerbi, Fernando Valente, Silmara A. O. Leite, Danillo Ewerton Oliveira Amaral, Gabriel Magalhães Nunes Guimarães, Plínio da Cunha Leal, Maristela Bueno Lopes, Luiz Carlos Bastos Salles, Liana Maria Torres de Araújo Azi, Amanda Gomes Fonseca, Lorena Ibiapina M. Carvalho, Francília Faloni Coelho, Bruno Halpern, Cynthia M. Valerio, Fabio R. Trujilho,  Antonio Carlos Aguiar Brandão, Ruy Lyra e Marcello Bertoluci. Rastreamento e Controle da Hiperglicemia no Perioperatório – Posicionamento Conjunto da Sociedade Brasileira de Diabetes (SBD), Sociedade Brasileira de Anestesiologia (SBA) e Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica (ABESO). Diretriz Oficial da Sociedade Brasileira de Diabetes (2025). DOI: 10.29327/5660187.2025-10 , ISBN: 978-65-5941-367-6.17. Singh LG, Ntelis S, Siddiqui T, Seliger SL, Sorkin JD, Spanakis EK. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2024;47(6):933-940. doi:10.2337/dc23-112918. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022;28(9):884-888. doi:10.1016/j.eprac.2022.06.00619. Umapathysivam MM, Morgan B, Inglis JM, et al. SGLT2 Inhibitor-Associated Ketoacidosis vs Type 1 Diabetes-Associated Ketoacidosis. JAMA Netw Open. 2024;7(3):e242744. Published 2024 Mar 4. doi:10.1001/jamanetworkopen.2024.274420. Fleming N, Hamblin PS, Story D, Ekinci EI. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. J Clin Endocrinol Metab. 2020;105(8):dgaa200. doi:10.1210/clinem/dgaa20021. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-622. Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022;386(21):2024-2034. doi:10.1056/NEJMra211501123. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa150472024. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa161192525. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa181238926. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa191130327. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa202219028. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa210703829. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa202481630. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in...

Raymond Mailhot, MD, MPH, University of Miami, Miami, FL Recorded on December 2, 2025 Raymond Mailhot, MD, MPH Department of Radiation Oncology University of Miami Miami, FL Join us with Dr. Raymond Mailhot from the University of Miami as we explore how social determinants of health shape patient experiences, treatment decisions, and outcomes. He discusses the importance of cultural competence in delivering equitable, patient-centered care and shares practical communication strategies to better engage patients and collaborate effectively. This episode offers actionable insights to strengthen relationships and improve overall care quality. Tune in today to gain practical strategies that will enhance your approach to patient-centered care and drive better outcomes! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Medical Debt Case Management Program for Patients Blood Cancer United Additional Resources for Patients

Michael Roth saß 27 Jahre für die SPD im Bundestag. Es dauerte lange, bis er sich eine psychische Erkrankung eingestand, sich Hilfe holte und aus der aktiven Politik ausstieg. In seinem Buch "Zonen der Angst" erzählt er, wie ihm das gelungen ist. Britta Bürger www.deutschlandfunkkultur.de, Im Gespräch

Bill Roggio analyzes the ISIS allegiance of Australian shooters, distinguishing ISIS's immediate caliphate goals from Al-Qaeda's patient state-building. He warns that while Al-Qaeda focuses on consolidating control in places like Somalia(Al-Shabaab), they remain a potent global threat capable of launching external attacks when strategically advantageous. 1842 Afghanistan

In this episode of Pray the Word on Revelation 1:9, David Platt calls us to live the Christian life with patient endurance.Over 3 billion people have never heard the gospel.At Radical, we're fueling 140 gospel projects in 42 countries to change that—equipping local leaders and mobilizing believers where Jesus is least known.Through December 31, every gift is doubled up to $750,000.Would you pray about being part of this?Learn more at Radical.net/everywhereExplore more content from Radical.

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In the competitive world of medical aesthetics, many practices struggle because they view "sales" as a dirty word. But here's the truth: sales is simply an extension of patient care. Terri Ross, a top industry expert, argues that the most successful cash-based practices shift their focus from pushing procedures to consulting on solutions. Your Actionable Takeaway: Abandon the "icky" sales stigma. Embrace emotional selling by asking deep, open-ended questions to uncover the true motivations behind a patient's desire for treatment. Patients buy on feeling, not just facts. When you genuinely serve, you automatically sell.

We'll bring you the latest on the investigation into the deaths of Rob Reiner and his wife Michele. An LA nursing home is still open despite three citations for deaths of its residents. Plus changes are coming to parking rates in Santa Monica. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.com Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency!Support the show: https://laist.com

Retatrutide is years away from FDA approval and yet the fight over access, price, control of this medication is already well underway. That's what this podcast is going to be about today. There's well over a hundred thousand people by my estimates who are already on some form of this medication today. And that should tell you enough about how disruptive this molecule is and will be. It is a game changer among game changer. We've been talking about it for three years here at On The Pen, well before any of your favorite gym bros were talking about Retatrutide. We were talking about Reta, who tried Retatrutide here at On The Pen. And that's because we identified this triple agonist as a game changer among game changers. So This is going to be a very Retatrutide heavy episode, and so I hope you'll join us and stick with us if this is a topic you enjoy, because I think this is really going to effectively lay the groundwork for what accessibility to this medication will look like. So let's get into it. Welcome to the On The Pen Podcast with your host, Dave Knapp. Welcome to the On The Pen, the weekly dose podcast. This is our weekly roundup in incretin memetic news. And frankly, there's no news that is bigger than Reta-Trutide news. Just find me any news that is bigger than the data that we got on Reta-Trutide. Now, we already did a video about the Triumph Phase II clinical trials that we got in osteoarthritis of the knee. You can go back and check out that video if you'd like more data. So we're not gonna super... rehash the data. We'll go over at a high level what the data showed us. We're not going to go over how the medicine works, because by now we all know that it's the triple agonist, right? If terzapatide was a dual agonist, GLP-GIP, Retatrutide is the triple agonist that adds to it a glucagon component, which is absolutely just shredding, shredding liver fat. It is absolutely revving up people's metabolism and showing a tremendous amount of weight loss. So let's get into what the weight loss looked like in this first trial, because there are longer obesity trials where, where the primary outcome is the weight loss this was again a specific trial in measuring pain reduction in folks with osteoarthritis of the knee but check out these numbers these are placebo adjusted meaning it's taking the two percent out that people lost on placebo but looking at these numbers Folks on one milligram over forty eight weeks lost seventeen percent. They bumped up to four milligrams. Those folks lost twenty two percent. So right there at the lowest dose, you're already reaching the efficacy of today's drugs that are on the market, like triseptide and semaglutide in their various forms. If you bumped up to eight milligrams, you saw twenty four percent placebo adjusted weight loss and at twelve milligrams, twenty six point four percent weight loss. Adding back in that two percent of the placebo that those on placebo loss, that's twenty eight point four percent weight loss in these forty eight weeks at the highest dose. When you adjust for some of the more real world outcomes, you kind of ding the numbers a little bit based upon people who quit the drug, et cetera. Those numbers look more like a twenty percent weight loss and twenty three point seven percent weight loss at the highest dose. But even then, you're still seeing a drug that is better than the current drugs that are on the market. around forty eight percent of patients on Retatrutide lost greater than twenty five percent. And then if you were at that twelve twelve milligram dose, that highest dose patients lost fifty nine percent of patients lost more than twenty five percent of their body weight. There was a subset that lost thirty percent of their body weight and some even over thirty five percent of their body weight on Retatrutide. So the lower doses compete with today's best drugs and the upper doses are entering into bariatric surgery level weight loss. And that's putting the whole obesity system on notice and probably a lot of surgeons nervous because typical body weight loss was something like the street sleeve gastrectomy. For example, it's about eighteen to twenty five percent body weight. The Roux-en-Y gastric bypass twenty five to thirty five percent weight loss or the duodenal switch thirty to forty percent weight loss. So the upper doses of Ritutrutide overlap with sleeve and bypass outcomes without any surgery. It's incredible. It is a game changer among game changer. It is the new benchmark in obesity medicine. And there's actually more data, like I said, landing in later twenty twenty six. The longer duration will historically, if history is a marker, equal more weight loss than we even see here at this forty eight weeks. We have an interview that will be airing later this week on our channel and on our podcast with our friend Mimi from Australia who just wrapped up her clinical trial on Retatrutide. They ended it like ten weeks early on her, which was a huge bummer to her. So we're going to hear from her because she had to end abruptly. We're going to hear her story, an incredible story. She's one of those folks that got up that thirty five percent body weight loss in the time that she was on Retatrutide. So, this is just showing you that these drugs are not simply an alternative to bariatric surgery. We are approaching a point in time where these are on par with bariatric surgery, and as people are on this Reta-Trutide trial, you see that these numbers aren't plateauing either. So we will see stronger weight loss numbers the longer that these folks are on this trial. And I think you'll see some of those numbers in that population of folks on the higher doses eclipse maybe even some of what we see with some of these bariatric surgeries. the real story that i think is taking shape here is not in how powerful Retatrutide is because we've literally been expecting or anticipating this kind of data for more than three years at on the pin we've been talking about this and i think that's sort of reflected in the fact that you didn't see this massive spike in eli lilly stock wall street was expecting this as well Um, so it was on par, I think with expectations, but the expectations are astronomical compared to previous options that were available to patients and all the innovation in the world. All of these drugs, we talked at last week about WV, E double Oh seven, the James Bond of weight loss that targets fat, not only targets fat loss, but it also targets the promotion of building of, of lean muscle mass. We're talking about an insane future in obesity medicine. But none of it means anything if people can't access it. And that's really where we are today in terms of ensuring that there's going to be an option for everyone. And that's sort of what I want to get into today, because Lilly wants Retatrutide to be classified as a biologic, so not a traditional small molecule drug like you've seen every other incretin and nutrient-stimulated hormone-treating obesity on the market to date. They're trying to get this classified as a biologic. Now, we talked about this before on the podcast. That matters in three major ways. It affects the exclusivity length of time that a pharmaceutical company has on a drug. That goes from, I believe, five years of market exclusivity to twelve. It affects compounding rules because biologics cannot be compounded. And then that gives the pharmaceutical companies a tremendous amount of pricing power in the marketplace, because essentially there's no competition and there's no competition for a long time. But this whole argument about getting this classified as a biologic is not about safety. It's about protection and we're going to get into it. So let's explain this here. This is why Retatrutide really is not a biologic arguably. So biologics are large proteins. There are hundreds of or even thousands of amino acids grown in living cells that are sensitive to tiny manufacturing changes. Retatrutide is a short chain peptide. It's chemically synthesized and it is below the traditional biological size thresholds when it comes to how those things are defined. We'll just leave it at that. So even though it acts like a biologic in the body, it's made like a drug. It's made like a small molecule drug. And if it's treated as a drug, they get, like I said, five years of market exclusivity. Now, really a lot of confusion around what this means, but essentially the first five years of the life of a drug, the patent can be challenged for a number of reasons. We've seen patent challenges right now are going on in the courts for both semaglutide and terzepatide. But these companies are guaranteed that five years of market exclusivity, no matter how those patent lawsuits shake out. That five years jumps to twelve years with the biologic. So ultimately, there's no biosimilars that are allowed during that twelve year window. Again, with terzapatidin and semaglutide, it's five years. They could lose their market exclusivity within five years of the release of the patent. twelve years with a biologic. So if they lose their patent challenges on Trezabitide, they still have some time left with market exclusivity for the drug. They likely will not lose those, but that jumps to twelve years. And I think the most important thing to understand about the reclassification of Reta-Trutide to a biologic would mean that, 503A and 503B pharmacies are effectively locked out of compounding this medication, 503Bs would have some latitude arguably, but they would face extreme barriers. Routine compounding becomes legally and technically restricted because biological status doesn't slow compounding down. It actually shuts the door or almost completely shuts the door. Biologics not only would allow Lilly to have longer market exclusivity, no compounding, but it would allow them to command a higher price in the marketplace because A, they get this designation and there's an assumption when they bring this to market that they're harder to manufacture, that they're harder to copy, that there are fewer negotiating alternatives for payers. They can command a higher price with the insurance companies, and the price pressure stays muted for much longer because, again, you don't have those pressures of compounding. You don't have the pressures externally from lawsuits that could end your market exclusivity in that first five years of the drug's existence. So there's just a lot of price pressure upwards on a biologic compared to a normal small molecule drug. And when there's no credible alternative or backup option, which to Retatrutide, there wouldn't be, it'd be the first drug that has bariatric surgery level results. The prices won't come down. They'll command a massive price and the prices won't come down. So let's talk about where this currently stands because ultimately the Eli Lilly went to the FDA. We've been covering this for well over a year, maybe close to two years now, a year and a half at least. Lily went to the FDA, they said, we want this classified as a biologic, here are the reasons why. The FDA initially said, no, we're not gonna do that. So Lily challenged that decision in court. So the point that we're at today is the court told the FDA to reconsider and better explain itself So the first no given to the FDA to Lilly didn't stick. The courts looked at it and they said, you need a better, you need to reconsider your decision and you need to explain your decision better to Lilly. So ultimately we're sitting now at the point where the court has made its decision that the FDA has to go back and now we await basically what the FDA has to say on this. But if this thing is classified as a biologic, that would be a massive massive loss for patients. Now, again, we're, we're focusing on the accessibility of this drug into the future. And, and I think that this is an important conversation to have. One of the interesting points that I have to bring into the conversation is the fact that I got to sit in on a, on a closed session question and answer with the media. I didn't get to answer or, excuse me, excuse me, ask a question at this time, but shortly after the most favored nations announcement, with eli lilly and the trump administration in the oval office that day there was a press briefing that i was invited to dave ricks was asked by max bayer reporter of endpoints who we've interviewed here on this very podcast and he was asked was Retatrutide included in the most favored nations discussions meaning will we get a cash pay version of Retatrutide uh that is you know circumventing the pbms uh will we get these cheaper prices will will it be be two hundred fifty dollars also and there was a hard no there was a hard no like no that was not included that was not part of these discussions even though what we heard from the trump administration was that those these companies that were jumping on to the most favored nations agreement were also agreeing to offer future drugs at most favored nations pricing now was lily saying that no they're not going to offer it at the it wasn't part of the negotiations in terms of the price points that they had discussed for triseptide maybe or did it mean altogether there won't be a cash pay option of this medication i don't know um that we would love to get clarity on But I highly doubt we're going to get any more information than necessary at this point in time. So, Reta-Trutide is being positioned to be a drug that, and well so, should be offered at a premium. This is a drug that is far exceeding the current drugs that are on the market. I think that we're gonna see even the indications of Reta-Trutide far beyond simple obesity, but it is going to be their crown jewel for the next decade, more than likely. Reta-Trutide is going to be a massive drug, and so they're attempting to build a moat around it. And these are things that we need to be aware of as a community so that we can hold our positions and conversations about these and basically, you know, be able to articulate to people in positions of power like this is an important thing to us. This is an important thing in the advocacy of obesity and sort of the next frontier of the fight of accessibility, which marches on. each and every day because of course the current drugs, while as great as they are and as much as access is expanding, there are still people with sicker or rather more advanced versions of metabolic disease that are gonna need these newer treatments and price is going to be a huge factor. So let's talk about the gray market right now because I think it's also nearly impossible to talk about this topic without including a discussion about the gray market because there are, as I mentioned at the outset, hundreds of thousands of people on this medication already. So research grade Retatrutide exists. It's in the gray markets of the Internet. It's where people are going and they're buying, you know, basically versions of these these peptides that are made in factories overseas. They're being imported into the United States, oftentimes illicitly in shipments that are marked as something else. The FDA has tried to crack down. There's no doctor involved in this. It's a very, that's why it's called the gray market, right? So it's not a prescription medicine, but the demand for this is massive. And all you have to do is really scroll your TikTok for about fifteen minutes. You're going to come across a insane amount of content on the topic of Retatrutide. An insane amount of, and oftentimes, you know, what I find most disturbing is oftentimes it looks like very young people. very young people taking Retatrutide. Crazy, it's crazy. But the demand is massive and there's a whole gray market for it proliferating over on TikTok and in the far reaches of the internet. And I would estimate that tens, if not hundreds of thousands of people are already or have already used it. And I think it's a testament to a to to the effectiveness of this drug. It's also a testament to the fact that there needs to be more guardrails, I think, around this stuff than there currently is, because gray markets appear and they thrive when legal access lags the reality of the demand for the medication. And you saw this earlier this week as we launched a petition to fight back against the Safe Drug Act of twenty twenty five, a drug, a drug act that is in theory designed to put guardrails around compounding. But in practice, I think is creating a new battlefield for Eli Lilly and Novo Nordisk to shut down compounding on the current classes of medications, which is why We as a community need to be loud about our opposition to it. If they were really concerned about the safety of compounds, they would do two very simple things. They would require reporting around the active pharmaceutical ingredient of a compound. Patients ought to be able to know where the actual source of their medication is coming from. And they should know that those places are FDA approved and inspected. And the second thing is they should require adverse event reporting. Those are required of 503Bs. They should be required of 503As as well. 503As are making a tremendous amount of money. They're making thousands and thousands of these scripts. So when there are adverse events, they should be required to report those to the FDA. Simple. None of that is in this bill. None of it. None of it. Instead, it seeks to put caps on the amount of compounds that can be made by a compound pharmacy without them having to report to the FDA. And then it seeks to codify the definition of essential copy. Again, all of these things that will become law and then argued in court and then a battlefield for Lilly to potentially win a legal battle and thwart compounding. It's creating a new battlefield for them. They're losing in the courts. They're losing with the current language that exists in the Food, Drug, and Cosmetic Act. So we create new language. We create new law. Just vague enough to pull some threads and hopefully win something in court. That's how I see it. You may see it differently. If you do, curious to hear from you. But if you want to fight back against this legislation, you can go to otplinks.com and fight back against that. piece of legislation, because I think that we need as a community to have our voices heard on this, especially those who have gotten healthier by way of compounded medications. So the rumor on the gray market, to get back and close the thought loop here, There's been no specific FDA cutoff announced, but what the rumors going around are that that the compounded versions of GLP ones, especially obesity medicine in the gray market, are all going to turn off like a sieve on January first. Now, I seem to feel like this is probably more of a marketing tactic by these companies to sell a whole bunch of peptides at the end of the year. I think that's probably creating some panic and probably panic buying on people's parts. And so these companies are benefiting greatly. Again, that's why there should be guardrails around this. There's no guardrails around this at all. I mean, at the end of the day, they can say whatever they want to say, so long as they cloak everything in research grade. And these rumors proliferate around and people spend thousands, tens of thousands of dollars. I've heard of people having twenty years worth of Retatrutide in their freezer. Why? For what purpose do you need that? So just a massive amount of money made in this gray market. And that's not to knock people who use it. I say this all the time, but I think it's worth qualifying the statement. It's not knocking people who use it. I get it. But at the same time, we're talking about an industry that is, there's no altruism here. They're in it for money just as much as Eli Lilly is, except they have actually done nothing in the way of advancing medicine. They've just taken intellectual property, copied it, and sold it to you with a label that says, don't put this in your body. So you know where I stand on the gray market. I've heard from many people who've been injured by gray market stuff. It's just what it is. It's a gray market. You're taking your health into your own hands. Please, whatever you're doing out there, as risky as it may be, please involve your doctor and let your doctor know what you're doing so you can be monitored for the things your doctor believes you should be monitored for if you're using this. But this all underscores, again, the need for accessibility to these medications, the need for us to be aware of the fact that a moat is already being built around the most advanced metabolic drug in the pipeline. And we just need to be aware so that when it comes time to fight, we're all ready and informed. And that's what this podcast is serving to do. Before we jump into the next topic, I do want to thank our sponsor, our headline sponsor of this podcast. is a company called Shed. Now, if you are looking for access to care for obesity, then look no further than our partners at Shed who believed in this podcast enough to help us do it full time. You can go to Trished.com and use code OTP25 to save twenty five percent at Trished.com, where you're going to get connected to a doctor who will when medically necessary prescribe medication to treat your obesity. You also get access to coaching. You'll get access to all sorts of medication, whether it's the branded or the compounded versions, depending on your specific situation. All of it is available at Trished.com. They use one of my favorite compound pharmacies in the game, Strive Pharmacy, which I've gotten the chance to dig into on my own. I really love what they do there. They're a It functionally operates a lot more like a 503B. Uh, and I think that they're doing great work over at a strive pharmacy. They partner with shed. So I just love this, this, and when we were looking for somebody to offer a compounded versions, I wanted to make sure that I trusted the pharmacy. People always ask me, Dave, who, who should I go to? I'm like the pharmacy matters more than anything because you want to trust the source of your medication. So try shed.com use code OTP25. Listen, you're going to want to learn about taking any new medication before you take it. Learn about the potential side effects. Learn about the trade offs. There's no free lunch, but all of the information that you're going to need, you can find it. Try shed.com and be familiarizing yourself with all of your options there. So thank you to Shed for being a wonderful partner here at On The Pen. Now let's talk about some data that dropped. We're talking about accessibility and all of the sort of advancements in the world mean very little if people can't access it. That's why I think this data that dropped this past week from our friends over at Rowe is incredible. Absolutely game changing data. So check out this data. Real world telehealth data looking at sixty eight weeks. This is looking at patients who were enrolled in their row body program and on a GLP one specifically some maglutide mean weight loss in this study looked at again patients in over sixty eight weeks. The mean weight loss was sixteen point six percent on average. Thirty three percent of patients lost more than twenty percent and the safety in this study and looking at this data match the clinical trials. So what we're seeing here is that care for obesity can be delivered through a telehealth platform at scale and match clinical trial results. So that scalability decides how many people get access. There are not enough doctors out there to serve the over hundred million people in the United States living with overweight or obesity. so when you hear these blowhard doctors online calling all telehealth platforms except their own a pill mill or as i like to say pin mill the data is actually showing something quite different in that this type of obesity care can be delivered at scale through telehealth platforms it can meet people where they're at and allow people to get care without the shame, without the stigma, without their doctor just pointing to the door and saying, if you want a GLP-I, get out of my office. I ain't going to get it here. How ridiculous. But these people can go to platforms like Rho or Shed or any number of telehealth platforms that are out there and not only get access to medicine, but get access to care. So of course, not all telehealth companies are created equal. Of course, not all compound pharmacies are created equal. You want to do your homework and all of that. But this is data that shows that This kind of care can be delivered at scale via a virtual platform and show similar results to a clinical trial. I think, and this is peer reviewed data, and I think that this is just absolutely great news because when we talk about the problem, we need scalable solutions. The old brick and mortar ain't going to work when you don't have enough doctors to serve enough patients. If we want to get life-changing treatments like ritatratide or terzapatide, semaglutide, whatever, into the hands of the people who need it the most, we need companies to innovate scalable tech platforms that can meet patients where they are, that can leverage current technologies to find people the care that they need. And in this case, it's access to a doctor. It's access to a platform. It's access to prescription medication when appropriately prescribed. And it can be done, and it is being done. So I think this is great news, and will play a huge part in the future. As we talk about Retatrutide, even though it's a year and a half away, maybe a little bit longer, it's already exposing – the issues around accessibility and pricing. Hopefully there will be compounded versions available if they're medically necessitated, if there are shortages. We hope that the battleground for that is not already set and won by Lilly before this drug even comes to market. But there are strategies being done to keep people boxed out But I can tell you that whatever happens with Retatrutide, the future of obesity medicine is in virtual care. And platforms are rising to the occasion. Retatrutide hasn't reached patients yet, but it's already forcing the system to show us, you know, are you ready? Are you ready to deliver bariatric surgery level results at scale to the people who need them? So I am so thankful that you joined me here on this podcast today. Again, we love to talk about we're at a Retatrutide. If you're interested, we've been going live every Monday, Wednesday and Friday at eleven a.m. Central Time here on our YouTube channel, on our tick tock, on our X platform. We're doing that because there's enough news to bring you just about every single day. And we've been doing it for the last couple of weeks. If you've enjoyed it, let me know in the comments of the video on YouTube. Send me an email at David on the pen dot com. Uh, so every single Monday, Wednesday, Friday, and then we do a weekly rundown of the obesity medicine news every Tuesday. That's what this is. The weekly dose podcast. You can catch this on all of the platforms that you listen to your podcasts on, and please make sure to leave us a five star rating and review before you log out of your podcast app. That helps so much. I don't think you guys understand how much that helps, uh, the work that we do here to just train the podcast algorithms that this one is worth listening to. I hope you enjoyed today's podcast. If you did, drop it a thumbs up, five-star review, subscribe on YouTube, do all the things. Thank you for being here, and thank you for being the best part of what we do. We will catch you on the next one. Thank you, my friends. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This episode is sponsored by Zomedica. Live from dvm360's Fetch Kansas City conference, host Adam Christman, DVM, MBA, sits down with Nicole Westfall, MBA, senior vice president of marketing at Zomedica. In this episode, they explore the benefits of PulseVet Shock Wave Therapy and The Assisi Loop, highlighting how these innovative tools provide noninvasive, effective pain management for patients suffering from chronic conditions.

What if your primary care doctor could be your wellness coach too? In this eye-opening conversation, we explore a revolutionary approach to healthcare that's changing the game for young professionals seeking optimal health and longevity.Meet Chloe Harrouche, the visionary behind The Lanby, a modern concierge medicine service tailored for health-conscious millennials. Inspired by her own journey as a young cancer survivor, she recognized a critical gap in our healthcare system - the lack of emphasis on prevention and holistic wellness. Reimagining Primary Care, The Lanby is bridging the divide between conventional medicine and integrative health. Topics Covered:

Torey Van Oot from Axios joins Adam and Jordana.

In episode 63 of Going anti-Viral, Dr Mari Kitahata joins host Dr Michael Saag to discuss the role of outcomes research on clinical decisions for patient care. Dr Kitahata is a Professor of Medicine at the University of Washington (UW) in the Division of Allergy and Infectious Diseases. For more than 3 decades, she has directed the UW/Fred Hutch Center for AIDS Research (CFAR) Clinical Research Core. Dr Kitahata's research focuses on improving long-term outcomes for people with HIV and she has led studies demonstrating key determinants of increased survival in people with HIV including early initiation of antiretroviral therapy and care managed by physicians with greater HIV experience. Dr Kitahata discusses the significance of outcomes research in clinical settings, particularly in the context of HIV care. She explains the differences between efficacy and effectiveness, the challenges faced in observational studies, and the importance of statistical techniques to address biases. Dr Kitahata and Dr Saag discuss the role of electronic medical records (EMRs) in enhancing data collection and the necessity of data validation through adjudication processes. Additionally, the conversation touches on the importance of patient-reported outcomes and the limitations of EMR data, including issues of misclassification. Finally, Dr Saag and Dr Kitahata discuss the distinction between predictive modeling and etiologic modeling in research, underscoring the complexities of clinical care and the future directions for outcomes research.0:00 – Introduction2:30 – Efficacy versus effectiveness5:51 – Challenges in outcomes research8:27 – Statistical techniques in observational studies16:13 – The role of electronic medical records19:36 – Patient-reported outcomes and their importance22:18 – Data validation and adjudication28:30 – Limitations of observational data35:08 – The future of outcomes research __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

AEM Podcast host Ken Milne, MD, and guest skeptic Suchismita Datta, MD, interview lead author Brian Driver, MD. Learn more in the accompanying Hot Off the Press article available in The Skeptics' Guide to Emergency Medicine.

For 17 December 2025, December 17, based on Matthew 1:1-17

In this episode of the JIMD Podcast, Terry G. J. Derks, Alessandro Rossi, Sarah C. Grünert and Yunkoo Kang talk about the evolving role of continuous glucose monitoring (CGM) in liver glycogen storage diseases. The conversation spans international consensus on CGM use and an exciting deep-learning approach to predicting hypoglycaemia, pointing towards more personalised and preventive care for people living with GSD. State of the Art and Consensus Statements by Healthcare Providers, Patients, and Caregivers on Continuous Glucose Monitoring in Liver Glycogen Storage Diseases Terry G. J. Derks, et al https://doi.org/10.1002/jimd.70040 and A deep learning approach for blood glucose monitoring and hypoglycemia prediction in glycogen storage disease Ji Seung Ryu, et al https://www.nature.com/articles/s41598-025-97391-8

Welcome back to Fill Me In! We're kicking off the holidays in our Christmas PJs for a special episode requested by one of Nicole's amazing patients.Jon and Nicole dive deep into the world of aesthetics for clients 50 and older. We discuss the unique challenges and considerations when treating aged tissue, volume loss, and skin laxity that comes with environmental exposure and hormonal changes.Whether you're an injector or a patient, we cover:➡️Why the consultation is different for this demographic.➡️The importance of honesty and empathy in setting realistic expectations.➡️Why treating the skin integrity first is non-negotiable (lasers, biostimulators, microneedling).➡️Avoiding common pitfalls, like injecting neurotoxins too low.➡️Crucial health screenings: dental work and vaccines.Plus, Jon's candid thoughts on new trends and misinformation in the industry!***DISCLAIMER***The content of this episode of Fill Me In: An Aesthetics Podcast is intended for educational and informational purposes only and does not constitute medical advice. The hosts, guests, and producers of this podcast do not endorse or recommend the off-label use of any medical product without proper clinical training, patient assessment, and full informed consent. Listeners are strongly advised to consult with their healthcare providers and adhere to all applicable laws and regulatory guidelines. We expressly disclaim any and all liability for any outcomes related to the use or misuse of the information presented in this episode.Fill Me In is hosted by Jonathan LeSuer, MSN, NP-C and Nicole Bauer, MSN, APRN, FNP-BC. Follow Fill Me In on Instagram!https://www.instagram.com/thefillmeinpod/Follow Nicole on Instagram:https://www.instagram.com/aestheticnursenicole/Nicole's Patreon:https://www.patreon.com/aestheticnursenicole?utm_source=searchExhibit Medical Aesthetics website:https://exhibitmedicalaesthetics.com/Follow Jon on Instagram:https://www.instagram.com/injectorjon/Jon's Patreon:https://www.patreon.com/Injectorjon?utm_source=searchTox and Pout Aesthetics website:https://toxandpout.com/Join Moxie! Is the business side of your Med Spa overwhelming? Moxie is the all-in-one growth system built to help you scale without the stress. Get software, marketing, compliance tools, and expert coaching all in one place. Fill Me In listeners get $500 off their launch fee! ➡️ Visit www.joinmoxie.com/fillmein Producer of Fill Me In: Joey Ginexi#FillMeInPod #AestheticInjector #50PlusAesthetics #AgingGracefully #MatureSkinCare #CosmeticInjections #AestheticNurse #InjectorLife #FacialBalancing #Biostimulators #Sculptra #DermalFillers #BotoxTips #MedSpaLife #AestheticEducation #CosmeticSurgery #SkinLaxity #ConsultationTips #AestheticBusiness

A mysterious man collapses on the steps of a church with no identification and no explanation — but when patients near him start making impossible recoveries, a nurse discovers his gift comes with a devastating price.IN THIS EPISODE: “The Healing Touch” by Keith ConradFully Produced Version: https://www.auditoryanthology.com/2025/01/28/tales-from-the-blue-line-the-healing-touch/ MORE Stories Like This: https://www.auditoryanthology.com=====Originally aired: December 15, 2025EPISODE PAGE (includes sources): https://weirddarkness.com/TheHealingTouchABOUT WEIRD DARKNESS: Weird Darkness is a true crime and paranormal podcast narrated by professional award-winning voice actor, Darren Marlar. Seven days per week, Weird Darkness focuses on all thing strange and macabre such as haunted locations, unsolved mysteries, true ghost stories, supernatural manifestations, urban legends, unsolved or cold case murders, conspiracy theories, and more. On Thursdays, this scary stories podcast features horror fiction along with the occasional creepypasta. Weird Darkness has been named one of the “Best 20 Storytellers in Podcasting” by Podcast Business Journal. Listeners have described the show as a cross between “Coast to Coast” with Art Bell, “The Twilight Zone” with Rod Serling, “Unsolved Mysteries” with Robert Stack, and “In Search Of” with Leonard Nimoy.#WeirdDarkness #HealingPowers #HospitalHorror #ScaryStories #MedicalMystery #SupernaturalGift #TrueScaryStories #MysteriousStranger #DarkFiction #MiracleHealing

In this episode of Stories Worth Hearing, host John Quick sits down with Dr. Mary Talley Bowden for an open and personal conversation about her journey into medicine and the experiences that shaped her views as a physician. Dr. Bowden reflects on when she first decided to pursue a medical career and how years of working directly with patients influenced her approach to care.The conversation explores what she witnessed during the COVID years that raised serious concerns for her as a doctor, and how those experiences led her to speak more openly about patient choice, informed consent, and trust in the healthcare system. Dr. Bowden also discusses why she founded Americans for Health Freedom, what the organization stands for, and why empowering patients to ask questions and take an active role in their health matters now more than ever.She also shares why she decided to write her book, Dangerous Misinformation: The Virus, the Treatments, and the Lies, and what she hopes readers take away from it. The episode includes reflections on her recent appearance on The Joe Rogan Experience and what it was like stepping onto one of the largest media platforms in the world. This is a thoughtful, human focused conversation about medicine, responsibility, and the real stories behind the headlines.Learn more and explore Dr. Bowden's work:Americans for Health Freedom: https://www.americansforhealthfreedom.org/BreatheMD: https://breathemd.org/Dangerous Misinformation: The Virus, the Treatments, and the Lies: https://amzn.to/48GbiTQ

Join this channel to get access to exclusive members only videos:https://www.youtube.com/channel/UCQTAVxA4dNBCoPdHhX9nnoQ/joinJoin Members Only On My Website. 7 day free trial. Save 25% when you choose an annual Membership plan. Cancel anytime:https://understandingrelationships.com/plansJoin Members Only on Spotify:https://podcasters.spotify.com/pod/show/coachcoreywayne/subscribeHow to know if you're sabotaging your success or if you're simply impatient.In this video coaching newsletter I discuss an email update from a 26 year old viewer who bartends, plays in a band and is living the rockstar lifestyle most guys dream of. However, he got out of a toxic relationship 2 years ago and says he self sabotages his opportunities with women he really likes while he beds countless beautiful women he's not that into. He wonders if maybe he's simply being impatient about meeting a great woman to have a relationship with.If you have not read my book, “How To Be A 3% Man” yet, that would be a good starting place for you. It is available in Kindle, iBook, Paperback, Hardcover or Audio Book format. If you don't have a Kindle device, you can download a free eReader app from Amazon so you can read my book on any laptop, desktop, smartphone or tablet device. Kindle $9.99, iBook $9.99, Paperback $29.99 or Hardcover 49.99. Audio Book is Free $0.00 with an Audible membership trial or buy it for $19.95. Here is the link to Audible to get the audiobook version:https://www.audible.com/pd/B01EIA86VC/?source_code=AUDFPWS0223189MWT-BK-ACX0-057626&ref=acx_bty_BK_ACX0_057626_rh_usHere is the link to Amazon to purchase Kindle, Paperback or Hardcover version:http://amzn.to/1XKRtxdHere is the link to the iBookstore to purchase iBook version:https://geo.itunes.apple.com/us/book/how-to-be-3-man-winning-heart/id948035350?mt=11&uo=6&at=1l3vuUoHere is the link to the iTunes store to purchase the iTunes audio book version:https://geo.itunes.apple.com/us/audiobook/how-to-be-a-3-man-unabridged/id1106013146?at=1l3vuUo&mt=3You can get my second book, “Mastering Yourself, How To Align Your Life With Your True Calling & Reach Your Full Potential” which is also available in Kindle $9,99, iBook $9.99, Paperback $49.99, Hardcover $99.99 and Audio Book format $24.95. Audio Book is Free $0.00 with an Audible membership trial. Here is the link to Audible to get the audiobook version:https://www.audible.com/pd/B07B3LCDKK/?source_code=AUDFPWS0223189MWT-BK-ACX0-109399&ref=acx_bty_BK_ACX0_109399_rh_usHere is the link to Amazon to purchase Kindle, Paperback or Hardcover version:https://amzn.to/2TQV2XoHere is the link to the iBookstore to purchase iBook version:https://geo.itunes.apple.com/us/book/mastering-yourself-how-to-align-your-life-your-true/id1353139487?mt=11&at=1l3vuUoHere is the link to the iTunes store to purchase the iTunes audio book version:https://geo.itunes.apple.com/us/audiobook/mastering-yourself-how-to-align-your-life-your-true/id1353594955?mt=3&at=1l3vuUoYou can get my third book, “Quotes, Ruminations & Contemplations” which is also available in Kindle $9,99, iBook $9.99, Paperback $49.99, Hardcover $99.99 and Audio Book format $24.95. Audio Book is Free $0.00 with an Audible membership trial. Here is the link to Audible to get the audiobook version:https://www.audible.com/pd/B0941XDDCJ/?source_code=AUDFPWS0223189MWT-BK-ACX0-256995&ref=acx_bty_BK_ACX0_256995_rh_usHere is the link to Amazon to purchase Kindle, Paperback or Hardcover version:https://amzn.to/33K8VwFHere is the link to the iBookstore to purchase iBook version:https://books.apple.com/us/book/quotes-ruminations-contemplations/id1563102111?itsct=books_box_link&itscg=30200&ct=books_quotes%2C_ruminations_%26_contemplatio&ls=1